

Drug and Therapeutics Committee – Minutes –unapproved

Date / Time Thursday 9th March 2017
Venue The Board Room, Alderson House, HRI
Chair Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points Mrs Susan Greene, Senior Pharmacy Technician (SG)

Quorate: Yes / No Yes

Attendance Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG)
Mr P O'Brien, Deputy Chief Pharmacist
Dr A Sampson, Infectious Diseases Consultant
Dr H Klonin, Consultant Paediatrician
Mr K McCorry, Medicines Management, East Riding
Dr O Ogunbambi, Consultant Rheumatologist
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics
Prof M Lind, Vice Chair, Professor of Oncology
Dr F Umerah, Consultant Anaesthetist
Mr R Kapur, Vascular Surgeon

Apologies Dr Roper, Chair, Hull CCG
Caroline Grantham, Medicines Management Nurse, HEY
Dr S Raise, GP, East Riding CCG

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.03.01	Apologies	As above.					
2017.03.02	Declarations of Interest	None.					
2017.03.03	Minutes of the previous meeting	The minutes were accepted as a true record.					03/17
2017.03.04	Action Tracker	<p>Fluticasone furoate and Vilanterol (Revlar Ellipta) POB to discuss and clarify commissioning DOT with respiratory service manager. Ongoing & to be discussed at MMIG.</p> <p>Stalevo & generics Previously there was discussion by the committee regarding what happened with other branded products - when patients were changed onto a generic version, or were swapped from one generic version to another generic version. This to be put on the next D&TC agenda. AM had written to Dr Ming to propose that Sastravi is used instead of Stalevo.</p> <p>Bisphosphonates as supportive therapy for Breast Cancer Once Leeds replied, ML would write a local protocol - to be sent to HERPC for further discussion.</p> <p>Mepolizumab AM had written to applicant and SG had updated formulary.</p> <p>Cabozantinib POB had checked the status and had a letter to confirm it was FOC until publication of NICE guidance (due June/17).</p> <p>NICE Guidance - January 17 TA427/TA428/TA429 ML had asked Dr Vicky Brown (new</p>	<p>POB to clarify commissioning</p> <p>To go on next D&T Agenda</p> <p>Action Complete</p> <p>ML to write protocol and send to SG</p> <p>Action Complete</p> <p>Action Complete</p> <p>Action Complete</p>	<p>POB to ask service manager</p> <p>SG to agenda</p> <p>Ongoing - Dr Dhadda is preparing</p>	<p>POB/SG</p> <p>SG</p> <p>ML</p>	<p>4/17</p> <p>4/17</p> <p>4/17</p> <p>4/17</p>	<p></p> <p>4/17</p> <p></p> <p>3/17</p> <p>3/17</p> <p>3/17</p>

		<p>Chemotherapy Committee chair) to organise applications. TA 430 Sofosbuvir-velpatasvir - application now received and to be circulated to committee members.</p> <p>Pecfent (Fentanyl Nasal Spray) – Dr L O’Toole SG had amended formulary to include use for head and neck cancer, initiated by Consultant Oncologist. SG had added to HERPC agenda, to discuss status.</p> <p>New Product Request Ferracru (Ferric Maltol) - Dr S Sebastian ML had received correspondence from Dr Sebastian stating that the trials conducted so far are licensing trials, so do not compare with other iron preparations, as the inclusion criteria where that patients has already failed on oral iron preparations. The proposal is that only IBD clinicians will initiate, and patients will be monitored in hospital at week 4 and 8. If no response at week 4, to stop and if partial response, continue to week 8. This will therefore be suggested as a Red drug at HERPC. The committee accepted this and approved the application as above.</p> <p>Tiotropium (Braltus) 10microgram Inhalation Powder SG had added to Pharmacy computer & made stock available</p> <p>Chairs approval - Thalidomide - Orofacial Granulomatosis POB confirmed that funding was from NHSE. AM had written to Dr Diggory to ask about the patient - awaiting reply.</p> <p>NICE Guidance - November 16 ML informed the committee that Dr Vicky Brown is the new chair of the Trust Chemotherapy Committee. SG had prepared a list of outstanding NICE TAs for cancer agents and sent this to ML. ML had forwarded to Dr Brown for preparation of applications.</p>	Action Complete				3/17
			Actions Complete				3/17
			Action complete				3/17
			Action Complete				3/17
			Actions Complete				3/17
			Actions Complete				3/17
2017.03.05	New Product Requests	<p>Nicardipine hydrochloride 10mg/10ml solution for Injection - Dr R Rayessa It was accepted that there were a lack of licensed drugs to treat hypertension with an injectable agent, if a patient could not take oral medication. There was discussion about whether this agent should be restricted for stroke medicine only, but it was felt this restriction</p>	Approved. AM to write letter to Health Group Medical Directors, for	AM to write to applicant. AM to write to HG MD's	AM AM	4/17 4/17	

		was unnecessary, as it could be useful in other situations (as per the license), so was approved without restriction on the formulary.	information. SG to include on OQC escalation form.	SG to include on OQC form.	SG	4/17	
2017.03.06	NICE Guidance	<p>NICE Guidance February 2017</p> <p>Drug misuse prevention: targeted interventions https://www.nice.org.uk/guidance/ng64</p> <p>Spondyloarthritis in over 16s: diagnosis and management https://www.nice.org.uk/guidance/ng65</p> <p>Everolimus for advanced renal cell carcinoma after previous treatment https://www.nice.org.uk/guidance/ta432</p> <p>Apremilast for treating active psoriatic arthritis https://www.nice.org.uk/guidance/ta433</p> <p>Intrapartum care for healthy women and babies - review https://www.nice.org.uk/guidance/cg190</p> <p>Neuropathic pain in adults: pharmacological management in non-specialist settings - review https://www.nice.org.uk/guidance/cg173</p> <p>Osteoporosis: assessing the risk of fragility fracture - review https://www.nice.org.uk/guidance/cg146</p> <p>Healthcare-associated infections: prevention and control in primary and community care - review https://www.nice.org.uk/guidance/cg139</p> <p>Surgical site infections: prevention and treatment - review https://www.nice.org.uk/guidance/cg74</p>	<p>Noted.</p> <p>Noted.</p> <p>Noted.</p> <p>Noted.</p> <p>Noted.</p> <p>Noted, alongside previous Lyrica legal proceedings.</p> <p>Noted.</p> <p>Noted, not for HEY.</p> <p>Noted.</p>	<p>No formulary implications</p> <p>All drugs on formulary</p> <p>On formulary</p> <p>SG to amend formulary.</p> <p>No formulary implications</p> <p>No action - await NHSE formal advice</p> <p>No formulary implications</p> <p>No formulary implications</p>	<p>SG</p>	<p>4/17</p>	<p>3/17</p> <p>3/17</p> <p>3/17</p> <p>3/17</p> <p>3/17</p> <p>3/17</p> <p>3/17</p>
2017.03.07	MHRA Drug Safety Update	<p>February 2017</p> <p>Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease.</p>	Noted.	No further action			3/17

2017.03.08	Minutes from SMPC	None					03/17
2017.03.09	Minutes from HERPC	25th January 2017 - Paediatric Growth Hormone HERPC had discussed whether Paediatric Growth Hormone should be repatriated back to HEY, as a red drug, to prescribe and monitor in secondary care only. Commissioning still to be discussed. DC will follow up.	DC to discuss commissioning status	DC to follow up regarding commissioning status	DC	5/17	
2017.03.10	Correspondence Received	HEY Guideline to Medication Review In Falls The committee received a new guideline poster from the Trust falls committee to review. The guidance is based on PrescQIPP B87 Care Homes - Medication and falls guidance (https://www.prescqipp.info/). The committee agreed with the list of drugs documented. It was felt that, although the poster was part of a larger Trust guideline, that it should state on the document where the information comes from, who wrote it and the preparation date & review date. Pregabalin FP10(HP) prescriptions from HEY LL raised concerns at the last MMIG meeting, regarding a number of local deaths being reported in the last year, where pregabalin was involved. There were concerns as to whether HEY were issuing excessive FP10(HP)s, which could contribute to abuse/overdose in our community. POB had sent the committee a spreadsheet report showing HEY FP10(HP) prescribing of pregabalin in the last year. There were 50 prescriptions, of which 8 were from A&E. Therefore it was felt that the issue is not primarily from HEY. The Committee suggested that the Chief Medical Officer could do a letter, or include this in a newsletter, to make Doctors aware of the situation in the community.	Approved with these minor amendments to the document Include pregabalin overdoses in report to OQC, as well as communication issues generally, as the committee were unsure if the CMO newsletter was still being produced.	SPG to feed comments back to Marie Miller SG to include in OQC escalation report	SPG SG	4/17 4/17	
2017.03.11	Chairs approvals	Sofosbuvir–velpatasvir for treating chronic hepatitis C - NICE TA430. AM had granted permission to start use in line with NHSE & NICE, prior to receipt of an application.	Application now received.	SG to circulate.	SG	4/17	

		Gemtuzumab ozogamicin (Mylotarg) for treating acute myeloid leukaemia - Dr Sahra Ali	Noted.				3/17
2017.03.12	Issues To Escalate To Operational Quality Committee	Nicardipine hydrochloride 10mg/10ml solution for Injection - approved for use when oral agents were unsuitable. Pregabalin abuse/overdose issues in the community.	Escalate	SG to include in OQC escalation report	SG	4/17	
2017.03.13	Any Other Business	None.					03/17
2017.03.14	Date and Time of Next Meeting	Date – 13/04/17 Time – 8.15am-9.30am Venue – Board Room, HRI					